Half a year after the FDA snatched back an approval for TG Therapeutics’ first-in-class lymphoma med Ukoniq, the company has landed a regulatory win. Wednesday, TG snared U.S. approval for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback